Lavie O, et al. - In a nonselective group of patients diagnosed during 1994–99, researchers sought to compare 5, 10 and 15 year survival in invasive epithelial ovarian cancer, between patients with and without BRCA1/2 germ line mutation. According to results, women with BRCA1/2 mutation invasive EOC carriers have all-cause mortality lower than non-carriers for 5, 10, and 15 years. Being a carrier has been related to a 26% decrease in mortality over non-carriers in the first 5 years. In the following years, being a BRCA carrier was not linked to better survival for women who survived 5 years or more. These outcomes might have implications for BRCA carrier patients ' clinical management and for their prognosis prediction.